Myotonia Congenita Mutation Enhances the Degradation of Human CLC-1 Chloride Channels

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Lee, Ting Ting ^a   Zhang, Xiao Dong ^b   Chuang, Chao Chin ^a   Chen, Jing Jer ^a   Chen, Yi An ^a   Chen, Shu Ching ^c   Chen, Tsung Yu ^b   Tang, Chih Yung ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; PROTEIN CLC 1; UNCLASSIFIED DRUG; VOLTAGE GATED CHLORIDE CHANNEL;

ARTICLE; BIOCHEMISTRY; CELL DENSITY; CELL SURFACE; CONTROLLED STUDY; EMBRYO; ENDOSOME; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; LOW TEMPERATURE; LYSOSOME; MUTATIONAL ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SURFACE PROPERTY; THOMSEN DISEASE; WHOLE CELL; WILD TYPE;

ANIMALS; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; CHLORIDE CHANNELS; COS CELLS; ELECTROPHYSIOLOGICAL PROCESSES; ENDOSOMES; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; LYSOSOMES; MUTATION; MYOTONIA CONGENITA; PROTEOLYSIS; TEMPERATURE;

EID: 84873733768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055930     Document Type: Article

References (60)

1. Jurkat-Rott K, Lerche H, Lehmann-Horn F, (2002) Skeletal muscle channelopathies. J Neurol 249: 1493-1502.
2. Steinmeyer K, Ortland C, Jentsch TJ, (1991) Primary structure and functional expression of a developmentally regulated skeletal muscle chloride channel. Nature 354: 301-304.
3. Bretag AH, (1987) Muscle chloride channels. Physiol Rev 67: 618-724.
4. Bryant SH, Morales-Aguilera A, (1971) Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids. J Physiol 219: 367-383.
5. Dulhunty AF, (1979) Distribution of potassium and chloride permeability over the surface and T-tubule membranes of mammalian skeletal muscle. J Membr Biol 45: 293-310.
6. Saviane C, Conti F, Pusch M, (1999) The muscle chloride channel ClC-1 has a double-barreled appearance that is differentially affected in dominant and recessive myotonia. J Gen Physiol 113: 457-468.
7. Miller C, (1982) Open-state substructure of single chloride channels from Torpedo electroplax. Philos Trans R Soc Lond B Biol Sci 299: 401-411.
8. Miller C, White MM, (1984) Dimeric structure of single chloride channels from Torpedo electroplax. Proc Natl Acad Sci U S A 81: 2772-2775.
9. Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R, (2002) X-ray structure of a ClC chloride channel at 3.0 A reveals the molecular basis of anion selectivity. Nature 415: 287-294.
10. Dutzler R, Campbell EB, MacKinnon R, (2003) Gating the selectivity filter in ClC chloride channels. Science 300: 108-112.
11. Feng L, Campbell EB, Hsiung Y, MacKinnon R, (2010) Structure of a eukaryotic CLC transporter defines an intermediate state in the transport cycle. Science 330: 635-641.
12. Chen TY, (2005) Structure and function of clc channels. Annu Rev Physiol 67: 809-839.
13. Lossin C, George AL Jr, (2008) Myotonia congenita. Adv Genet 63: 25-55.
14. Colding-Jorgensen E, (2005) Phenotypic variability in myotonia congenita. Muscle Nerve 32: 19-34.
15. Pusch M, (2002) Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum Mutat 19: 423-434.
16. Ptacek LJ, Johnson KJ, Griggs RC, (1993) Genetics and physiology of the myotonic muscle disorders. N Engl J Med 328: 482-489.
17. Kubisch C, Schmidt-Rose T, Fontaine B, Bretag AH, Jentsch TJ, (1998) ClC-1 chloride channel mutations in myotonia congenita: variable penetrance of mutations shifting the voltage dependence. Hum Mol Genet 7: 1753-1760.
18. Duffield M, Rychkov G, Bretag A, Roberts M, (2003) Involvement of helices at the dimer interface in ClC-1 common gating. J Gen Physiol 121: 149-161.
19. Weinberger S, Wojciechowski D, Sternberg D, Lehmann-Horn F, Jurkat-Rott K, et al. (2012) Disease-causing mutations C277R and C277Y modify gating of human ClC-1 chloride channels in myotonia congenita. J Physiol 590: 3449-3464.
20. Wu FF, Ryan A, Devaney J, Warnstedt M, Korade-Mirnics Z, et al. (2002) Novel CLCN1 mutations with unique clinical and electrophysiological consequences. Brain 125: 2392-2407.
21. Macias MJ, Teijido O, Zifarelli G, Martin P, Ramirez-Espain X, et al. (2007) Myotonia-related mutations in the distal C-terminus of ClC-1 and ClC-0 chloride channels affect the structure of a poly-proline helix. Biochem J 403: 79-87.
22. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, et al. (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761-764.
23. French PJ, van Doorninck JH, Peters RH, Verbeek E, Ameen NA, et al. (1996) A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J Clin Invest 98: 1304-1312.
24. Papponen H, Toppinen T, Baumann P, Myllyla V, Leisti J, et al. (1999) Founder mutations and the high prevalence of myotonia congenita in northern Finland. Neurology 53: 297-302.
25. Papponen H, Nissinen M, Kaisto T, Myllyla VV, Myllyla R, et al. (2008) F413C and A531V but not R894X myotonia congenita mutations cause defective endoplasmic reticulum export of the muscle-specific chloride channel CLC-1. Muscle Nerve 37: 317-325.
26. Kisselev AF, Goldberg AL, (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739-758.
27. Lee DH, Goldberg AL, (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8: 397-403.
28. Cheng J, Wang H, Guggino WB, (2004) Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL. J Biol Chem 279: 1892-1898.
29. Skovronsky DM, Pijak DS, Doms RW, Lee VM, (2000) A distinct ER/IC gamma-secretase competes with the proteasome for cleavage of APP. Biochemistry 39: 810-817.
30. Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G, (2005) BACE is degraded via the lysosomal pathway. J Biol Chem 280: 32499-32504.
31. Bagola K, Mehnert M, Jarosch E, Sommer T, (2011) Protein dislocation from the ER. Biochim Biophys Acta 1808: 925-936.
32. Vembar SS, Brodsky JL, (2008) One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 9: 944-957.
33. Sharma M, Pampinella F, Nemes C, Benharouga M, So J, et al. (2004) Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 164: 923-933.
34. Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, et al. (2010) Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329: 805-810.
35. Ling H, Vamvakas S, Gekle M, Schaefer L, Teschner M, et al. (1996) Role of lysosomal cathepsin activities in cell hypertrophy induced by NH4Cl in cultured renal proximal tubule cells. J Am Soc Nephrol 7: 73-80.
36. Wan J, Khanna R, Sandusky M, Papazian DM, Jen JC, et al. (2005) CACNA1A mutations causing episodic and progressive ataxia alter channel trafficking and kinetics. Neurology 64: 2090-2097.
37. Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, et al. (2006) Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113: 365-373.
38. Sun C, Tranebjaerg L, Torbergsen T, Holmgren G, Van Ghelue M, (2001) Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia. Eur J Hum Genet 9: 903-909.
39. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, et al. (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354: 526-528.
40. Cai ZW, Liu J, Li HY, Sheppard DN, (2011) Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis. Acta Pharmacol Sin 32: 693-701.
41. Miki H, Zhou Z, Li M, Hwang TC, Bompadre SG, (2010) Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs. J Biol Chem 285: 19967-19975.
42. Hebert DN, Molinari M, (2007) In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev 87: 1377-1408.
43. Ellgaard L, Molinari M, Helenius A, (1999) Setting the standards: quality control in the secretory pathway. Science 286: 1882-1888.
44. Ibba M, Soll D, (1999) Quality control mechanisms during translation. Science 286: 1893-1897.
45. Ma D, Jan LY, (2002) ER transport signals and trafficking of potassium channels and receptors. Curr Opin Neurobiol 12: 287-292.
46. Vandenberghe W, Bredt DS, (2004) Early events in glutamate receptor trafficking. Curr Opin Cell Biol 16: 134-139.
47. Nufer O, Guldbrandsen S, Degen M, Kappeler F, Paccaud JP, et al. (2002) Role of cytoplasmic C-terminal amino acids of membrane proteins in ER export. J Cell Sci 115: 619-628.
48. Wang X, Matteson J, An Y, Moyer B, Yoo JS, et al. (2004) COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. J Cell Biol 167: 65-74.
49. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, et al. (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770-774.
50. Ward CL, Kopito RR, (1994) Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 269: 25710-25718.
51. Mihic A, Chauhan VS, Gao X, Oudit GY, Tsushima RG, (2011) Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation. PLoS One 6: e18273.
52. Ciechanover A, (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6: 79-87.
53. Balch WE, Morimoto RI, Dillin A, Kelly JW, (2008) Adapting proteostasis for disease intervention. Science 319: 916-919.
54. Douglas PM, Dillin A, (2010) Protein homeostasis and aging in neurodegeneration. J Cell Biol 190: 719-729.
55. Aridor M, Balch WE, (1999) Integration of endoplasmic reticulum signaling in health and disease. Nat Med 5: 745-751.
56. Aridor M, Hannan LA, (2000) Traffic jam: a compendium of human diseases that affect intracellular transport processes. Traffic 1: 836-851.
57. Aridor M, Hannan LA, (2002) Traffic jams II: an update of diseases of intracellular transport. Traffic 3: 781-790.
58. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387.
59. Wong W, Newell EW, Jugloff DG, Jones OT, Schlichter LC, (2002) Cell surface targeting and clustering interactions between heterologously expressed PSD-95 and the Shal voltage-gated potassium channel, Kv4.2. J Biol Chem 277: 20423-20430.
60. Tseng PY, Bennetts B, Chen TY, (2007) Cytoplasmic ATP inhibition of CLC-1 is enhanced by low pH. J Gen Physiol 130: 217-221.